Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
  • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
  • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G18/00—Polymeric products of isocyanates or isothiocyanates
  • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
  • C08G18/08—Processes
  • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G18/00—Polymeric products of isocyanates or isothiocyanates
  • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
  • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
  • C08G18/40—High-molecular-weight compounds
  • C08G18/48—Polyethers
  • C08G18/4804—Two or more polyethers of different physical or chemical nature
  • C08G18/4812—Mixtures of polyetherdiols with polyetherpolyols having at least three hydroxy groups
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G18/00—Polymeric products of isocyanates or isothiocyanates
  • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
  • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
  • C08G18/40—High-molecular-weight compounds
  • C08G18/62—Polymers of compounds having carbon-to-carbon double bonds
  • C08G18/6212—Polymers of alkenylalcohols; Acetals thereof; Oxyalkylation products thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G18/00—Polymeric products of isocyanates or isothiocyanates
  • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
  • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
  • C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
  • C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
  • C08G18/6666—Compounds of group C08G18/48 or C08G18/52
  • C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
  • C08G18/6681—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/32 or C08G18/3271 and/or polyamines of C08G18/38
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
  • C09J175/00—Adhesives based on polyureas or polyurethanes; Adhesives based on derivatives of such polymers
  • C09J175/04—Polyurethanes
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G2190/00—Compositions for sealing or packing joints

Definitions

• the present disclosure relates to adhesives and sealants formed from synthetic components for medical and surgical use with animal tissues in vivo.
• tissue adhesives or tissue sealants are currently available.
• One type of adhesive that is currently available is a
• cyanoacrylate adhesive has a high flexural modulus which can limit their usefulness.
• fibrin sealants are available. However, as with any natural material, variability in the material is frequently observed and, because the sealant is derived from natural proteins, there may be viral transmission concerns.
• Such a composition should be flexible and biocompatible and should be suitable for use as an adhesive or sealant.
• the disclosed compositions relate to synthetic adhesives and sealants for medical/surgical use.
• the biocompatible adhesive compositions include a functionalized triol and a functionalized diol, while the sealant compositions further include a multifunctional polyol and at least one amine cross linker.
• the triol and diol may be functionalized with a polyalkylene oxide having multiple isocyanate groups.
• compositions of the present disclosure may include biocompatible adhesives including
• X-Y-X- O [X-Y-X- O] 2 - R; wherein X is an isocyanate, Y is a polyalkylene oxide, and R can be alcohols, aliphatic polyesters, ketones, carbonates, anhydrides, and
• compositions of the present disclosure may include biocompatible sealants including a functionalized triol of formula
• the multifunctional alcohol may be of the formula
• E-X-Z-[(D) W -X] r wherein E is a hydrophilic polymer, X can be the same or different at each location and is an isocyanate, Z is a polyol, D is a bioabsorbable group, w is a number from 1 to 20, and r is a number from 1 to 10.
• Suitable amine cross linkers include primary amines, diamines, aromatic amines, polyamines, and polyamidoamines.
• compositions can be applied by a variety of methods, including spraying the compositions onto a surgical site.
• the present disclosure includes methods for closing wounds by applying a composition of the present disclosure to a wound and allowing the composition to set, thereby closing said wound.
• wounds may include, in embodiments, incisions.
• compositions of the present disclosure may also be utilized to seal leaks in animal.
• compositions of the present disclosure may be utilized to adhere a medical device, such as an implant, to a surface of animal tissue.
• the present disclosure relates to biocompatible compositions for use as tissue adhesives or sealants, which are biocompatible, non-immunogenic and biodegradable.
• the biocompatible compositions can be employed to adhere tissue edges, adhere medical devices (i.e. implants) to tissue, seal air/fluid leaks in tissues, and for tissue augmentation such as sealing or filling voids or defects in tissue.
• an "adhesive” is understood to mean a composition which adheres one thing to another, such as tissue edges to each other or a device, such as an implant, to tissue
• a “sealant” is understood to mean a composition which is applied to tissue and utilized to seal air/fluid leaks in tissue or seal or fill small voids or defects in tissue.
• the biocompatible compositions can be applied to living tissue and/or flesh of animals, including humans.
• tissue may include, but is not limited to, skin, bone, neuron, axon, cartilage, blood vessel, cornea, muscle, fascia, brain, prostate, breast, endometrium, lung, pancreas, small intestine, blood, liver, testes, ovaries, cervix, colon, stomach, esophagus, spleen, lymph node, bone marrow, kidney, peripheral blood, embryonic or ascite tissue.
• the first component of the biocompatible compositions of the present disclosure includes a functionalized triol.
• polyols which may be utilized to form functionalized triols in accordance with the present disclosure include, but are not limited to, polyether polyols; polyester polyols; block copolymers composed of branched chain ethoxylated alcohols; alkoxylated alcohols such as NEODOL ® which is sold commercially by Shell Chemical Company; polyvinyl alcohols; polyhydric alcohols; carboxylic acid esters of polyhydric alcohols; polyglycols; and polylactone polyols.
• suitable polyols for use as the functionalized triol include polyether-based polyols, polyester-based polyols such as
• polycaprolactone-based polyols and polyhydric alcohols such as glycerol, pentaerythritol, sorbitol, trimethyiol propane and diethylene glycol.
• the triol can be glycerol, trimethyiol propane, hexane-1 ,2,6-triol, or polycaprolactone triol.
• the functionalized triol may include degradable linkages so as to render the triol degradable.
• Suitable degradable linkages which can be optionally incorporated in the functionalized triol include, but are not limited to, hydrolytically labile ⁇ -hydroxy acids such as lactic acid, glycolic acid, and hydroxy-butyric acid, glycolide, lactide, lactones including ⁇ -caprolactone, carbonates such as trimethylene carbonate, ester ethers such as dioxanones including 1 ,4-dioxane- 2-one and 1 ,3-dioxane-2-one, diacids including succinnic acid, adipic acid, sebactc acid, malonic acid, glutaric acid, azelaic acid, phosphoesters such as ethyl dichlorophosphate, anhydrides including sebacic acid anhydride and azelaic acid anhydride, etc. and combinations thereof.
• each hydroxy group of the triol is functionalized.
• the triol can be functionalized with an isocyanate.
• Suitable isocyanates for functionalizing the triol include aromatic, aliphatic and alicyclic isocyanates, including polyisocyanates. Examples include, but are not limited to, aromatic diisocyanates such as 2,4-toluene diisocyanate, 2,6-toluene
• tetramethylxylylene diisocyanate tetramethylene diisocyanate, hexamethylene diisocyanate, lysine diisocyanate, 2 ⁇ methylpentane-1 ,5-diisocyanate, 3- methylpentane-1 ,5-diisocyanate, or 2,2,4-trimethylhexamethylene diisocyanate; and alicyclic diisocyanates such as isophorone diisocyanate, cyclohexane diisocyanate, hydrogenated xylylene diisocyanate, hydrogenated
• diphenylmethane diisocyanate or hydrogenated trimethylxylylene diisocyanate.
• isocyanates for functional izing such triols include, but are not limited to, toluene diisocyanate (TDI), 4,4'-diphenylmethane diisocyanate (MDI), hexane-1 ,6-diisocyanate (HDI), isophorone diisocyanate (IPDI), hexamethylene diisocyanate (HMDI), m-tetramethylxylylene diisocyanate (m-TMXDI), p-tetramethylxylylene diisocyanate (p-TMXDI), and combinations thereof.
• TDI toluene diisocyanate
• MDI 4,4'-diphenylmethane diisocyanate
• HDI hexane-1 ,6-diisocyanate
• IPDI isophorone diisocyanate
• HMDI hexamethylene diisocyanate
• m-TMXDI m-tetra
• an adduct of a diisocyanate with a hydrophilic polymer such as ethylene glycol or polyethylene glycol and use the resulting adduct to functionalize a triol in accordance with the present disclosure.
• the adduct may be formed by reacting the diisocyanate with a hydrophilic polymer such as a polyalkylene oxide ("PAO").
• PAO polyalkylene oxide
• polyalkylene oxides include polyethylene glycol (“PEG”), polyethylene oxide (“PEO”), polypropylene oxide (“PPO”), polyethylene glycols with lactide linkages, polypropylene glycol (“PPG”), polypropylene glycol-co-polyethylene oxide block or random copolymers, and poloxamers such as polyethylene oxide (PEO) copolymers with polypropylene oxide (PPO) such as the triblock PEO - PPO copolymers commercially available as PLURONICS® from BASF Corporation (Mt. Olive, NJ).
• PEO polyethylene oxide
• PPO polypropylene oxide
• PPO polypropylene oxide block or random copolymers
• poloxamers such as polyethylene oxide (PEO) copolymers with polypropylene oxide (PPO) such as the triblock PEO - PPO copolymers commercially available as PLURONICS® from BASF Corporation (Mt. Olive, NJ).
• PVA polyvinyl alcohol
• the adduct may first be prepared and then added to the triol to produce the functionalized triol of the present disclosure.
• the adduct can be formed by reacting an excess of a diisocyanate with the polyalkylene oxide to form an isocyanate terminated adduct as
• the isocyanate terminated adduct may then be reacted with a triol to produce a functionalized triol of the formula:
• X can be the same or different and is an isocyanate, including a polyisocyanate
• Y can be a polyalkylene oxide
• R is an alcohol, aliphatic polyester, ketone, carbonate, anhydride, or a combination thereof.
• X is hexamethylene diisocyanate
• Y is polyethylene glycol
• R is a lactone such as a polycaprolacto ⁇ e.
• the triol can have a molecular weight from about 200 g/mol to about 1500 g/mol, in embodiments from about 250 ⁇ /mol to about 1300 g/mol.
• This first component can be utilized by itself or in combination with a second component to form a surgical adhesive in accordance with the present disclosure.
• the second component can be a functionalized diol which can have the basic structure of:
• X is an isocyanate such as hexamethylene diisocyanate
• Y is a polyethylene glycol
• R is a polycaprolactone
• the functionalized diol can be present in an adhesive composition in an amount from about 10 to about 98 percent by weight of the composition, in embodiments from about 25 to about 95 percent by weight of the composition, typically from about 50 to about 90 percent by weight of the composition.
• the balance of the adhesive composition in such a case will be the first component, i.e., the functionalized triol, which can be from about 90 to about 2 percent by weight of the composition, in embodiments from about 75 to about 5 percent by weight of the composition, typically from about 50 to about 10 percent by weight of the composition.
• the weight ratio of the first component to the second component in the composition of the present disclosure is about 1 :9.
• the resulting adhesive composition will possess a branched structure with the functionalized triol, such as polycaprolactone triol, at the center and the functionalized diols branching out from said triol.
• the resulting adhesive composition of the present disclosure can be used in a medical/surgical capacity in place of, or in combination with, sutures, staples, clamps and the like.
• Optional components may be added to the composition to adjust its viscosity according to a specific application of use, e.g., as an adhesive or a sealant.
• Such optional components can include, for example, diethylene glycol dimethyl ether ("DIGLYME”), dimethylformamide (“DMP), anhydrides such as maleic anhydride, and combinations thereof.
• Thickening agents which can be used to adjust the viscosity of the compositions of the present disclosure include polycyanoacrylates, polylactic acid, polyglycolic acid, lactic-glycolic acid
• copolymers poly-3-hydroxybutyric acid, polyorthoesters, polyanhydrides, pectin, and combinations thereof.
• additives can be included so that they are present in an amount from about 1 to about 30 percent by weight of the composition, in embodiments from about 2 to about 15 percent by weight of the composition.
• stabilizers can also be added to the first and/or second component to increase the storage stability of the compositions of the present disclosure.
• Suitable stabilizers can include those which prevent premature polymerization such as quinones, hydroquinone, hindered phenols, hydroquinone monomethyl ether, catechol, pyrogallol, benzoquinone, 2-hydroxybenzoquinone, p-methoxy phenol, t-butyl catechol, butylated hydroxy anisole, butylated hydroxy toluene, or t-buty! hydroquinone.
• Suitable stabilizers can also include
• anhydrides silyl esters, sultones (e.g., ⁇ -chloro- ⁇ -hydroxy-o-toluenesulfonic acid- ⁇ -sultone), sulfur dioxide, sulfuric acid, sulfonic acid, sulfurous acid, lactone, boron trifluoride, organic acids, alkyl sulfate, alkyl sulfite, 3-sulfolene,
• alkylsulfone alkylsulfone, alkyl sulfoxide, mercaptan, alkyl sulfide and combinations thereof.
• an anhydride such as maleic anhydride, sebacic acid anhydride, and/or azelaic acid anhydride, can be used as a stabilizer.
• such stabilizers can be included so that they are present in an amount from about 0.01 to about 10 percent by weight of the composition, in embodiments from about 0.1 to about 2 percent by weight of the composition.
• solid supported catalysts may be used during synthesis to improve stability of the resulting adhesive composition.
• the presence of such catalysts may increase reactivity during use.
• Suitable catalysts are known to those skilled in the art and can include stannous octoate,
• the amount of catalyst employed can be from about 0.5 grams to about 50 grams per kilogram of the other components of the composition.
• the adhesiive composition of the present disclosure can be used for a number of different human and animal medical applications including, but not limited to, wound closure (including surgical incisions and other wounds), adhesives for medical devices (including implants), void fillers, and embolic agents. These adhesives may be used to bind tissue together either as a replacement of, or as a supplement to, sutures, staples, tapes and/or bandages. Use of the disclosed adhesive can eliminate or substantially reduce the number of sutures normally required during current practices, and eliminate the
• compositions of the present disclosure thus can be particularly useful for use with delicate tissues wlnere sutures, clamps or other conventional tissue closure mechanisms may cause further tissue damage.
• the adhesive composition of the present disclosure can be dispensed from a conventional adhesive dispenser, which typically provides mixing of the first and second components prior to the dispenser.
• a conventional adhesive dispenser typically provides mixing of the first and second components prior to the dispenser.
• Such dispensers are disclosed, for example, in U.S. Patent Nos. 4,978,336, 4,361 ,055, 4,979,942, 4,359,049, 4,874 ;1 368, 5,368,563, and 6,527,749, the disclosures of each of which are incorporated herein by reference.
• the adhesive composition of the present disclosure may be utilized as a void filler or to fill a defect in an animal's body, it may be advantageous to more precisely control the conditions and extent of cross-linking; in such a case, it may be desirable to partially cross-link the composition prior to its use to fill a void in animal tissue.
• the composition of the present disclosure may then be applied to the void or defect and allowed to set, thereby filling the void or defect.
• the two edges are
• composition of the present disclosure can thus be used as an adhesive to close a wound, including a surgical incision. In such a case, the composition of the present disclosure can be applied to the wound and allowed to set, thesreby closing the wound.
• the present disclosure is directed to a method for using the adhesive composition of the present disclosure to adhere a medical device to tissue, rather than secure two edges of tissue.
• a coating may be required on the medical device. In some aspects such a coating can include the
• the medical device includes an implant.
• Other medical devices include, but are not limited to, pacemakers, stents, shunts and the like.
• the composition of the present disclosure can be applied to the device, the tissue surface or both. The device, adhesive composition and tissue surface are then brought into contact with each other and the composition is allowed to set, thereby adhering the device and surface to each other.
• the present adhesive can also be used to prevent post surgical adhesions.
• the adhesive composition is applied and cured as a layer on surfaces of internal tissues in order to prevent the formation of adhesions at a surgical site during the healing process.
• the adhesive may be utilized to form implants such as gaskets, buttresses or pledgets for implantation.
• the adhesive composition can be used to attach skin grafts and position tissue flaps during reconstructive surgery. In still another embodiment, the adhesive can be used to close tissue flaps in periodontal surgery.
• the adhesive can be done by any conventional means. These include dripping, brushing, or other direct manipulation of the adhesive on the tissue surface, or spraying of the adhesive onto the surface. I'n open surgery, application by hand, forceps or the like is contemplated. In endoscopic surgery, the adhesive can be delivered through the cannula of a trocar, and spread at the site by any device known in the art.
• the first component i.e., the functionalized triol
• the second component optionally in combination with the second
• the sealant thus produced can be in the form of a sprayable composition capable of achieving both rapid cure and the formation of an adhesive barrier after application.
• the additional components for the sealant can include a
• this multifunctional alcohol such as a multifunctional polyol, and at least one amine cross linker.
• this multifunctional alcohol can be formed from a polyol, a hydrophilic polymer, a polyisocyanate, and optionally a
• the polyol portion of the multifunctional alcohol can be any biologically acceptable polyol for surgical use (i.e., non-toxic and biodegradable).
• Suitable polyols can include, for example, sorbitol, glycerol, pentaerythritol, mannitol, glucose, dextrose, sucrose, other polyhydric alcohols, and combinations thereof.
• sorbitol is used as the polyol of the multifunctional polyol.
• the polyol of the multifunctional alcohol can be functionalized with an adduct.
• the adduct can include at least one
• bioabsorbable group that is endcapped with a biocompatible compound.
• Suitable bioabsorbable groups include hydrolytically labile ⁇ -hydroxy acids such as lactic acid, glycolic acid, and hydroxy-butyric acid, glycolide, lactide, lactones including ⁇ -caprolactone, carbonates such as trimethylene carbonate, ester ethers such as dioxanones including 1 ,4-dioxane-2-one and 1 ,3-dioxane-2-one, diacids including succinnic acid, adipic acid, sebacic acid, malonic acid, glutaric acid, azelaic acid, phosphoesters such as ethyl dichlorophosphate, anhydrides including sebacic acid anhydride and azelaic acid anhydride, and the like, and combinations thereof.
• polylactic acid can be used as the bioabsorbable group.
• the bioabsorbable group may be endcapped with an isocyanate.
• Suitable isocyanates for endcapping the bioabsorbable group include the diisocyanates described above lor endcapping the functionalized polyol.
• the isocyanate can be a diisocyanate such as toluene
• TDI 4,4'-diphenylmethane diisocyanate
• HMDl 1,6-hexamethylene diisocyanate
• IPDI isophorone diisocyanate
• lysine diisocyanate 4,4'-oxybis(phenyl isocyanate
• the multifunctional alcohol may be further functionalized with a second adduct that includes at least one hydrophilic polymer.
• Suitable hydrophilic polymers are known to those skilled in the art and include those hydrophilic polymers described above for use in preparing the functionalized polyol.
• a PAO such as PEG can be utilized as the
• the hydrophilic polymer may be utilized to form an adduct similar to the adduct described above with respect to the functionalized polyol, i.e., the hydrophilic polymer is endcapped with an isocyanate, such as a diisocyanate described above for endcapping the functionalized polyol.
• E is the hydrophilic polymer
• X can be the same or different at each location and is an isocyanate as described above
• Z is a polyol component
• D is a bioabsorbable group
• w is a number from 1 to 20
• r is a number from 1 to 10.
• E is a polyethylene glycol
• X is a polyethylene glycol
• Z is D-sorbitol
• D lactide
• w is a number from 2 to 10
• r is a number from 2 to 5.
• the hydrophilic polymer can be lengthened or shortened to modify the viscosity of the multifunctional alcohol, thereby modifying the viscosity and barrier properties of the final sealant composition, as desired.
• the above multifunctional polyol may be combined with the functionalized triol, optionally in combination with the diol component described above, in situ in the presence of at least one amine cross linker to form a sealant composition of the present disclosure.
• Amine cross linkers which may be utilized include primary amines, diamines, aromatic amines, polyamines, polyamidoamines, and combinations thereof.
• Suitable amines which may be utilized as the amine cross linker include poly(allyl amine), poly(L-lysine), polyalkylene oxides having two or more amine functional groups, triethylamine, diisopropylethylamine (H ⁇ nig's base), N,N-dimethylethanolamine,
• diaminobicyclooctane N-ethylmorpholine, bis(2-dimethylaminoethyl)ether, N'.N'- dimethylpiperazine, N,N,N',N',N'-pentarnethyldiethylene triamine, N,N- dimethylcyclohexylamine, N, N-dimethylbenzy famine, N,N-dimethyl(ethylamine), N,N,N',N",N"-pentamethyl-diproylene triamine, 1 -(2-hydroxypropyl)imidazole, dimethyl coconut amine, dimethyl octylamine, dimethyl decylamine, dimethyl laurylamine, dimethylmyristylamine, dimethylpalmitylamine, dimethyl stearyl amine, dimethyl behenyl amine, pyridine, dimethylaminopyridine (DMAP), dimethyl pyridine, and the like.
• DMAP dimethylaminopyr
• Suitable amines for use as the at least one amine cross linker include, but are not limited to, ethylene diamine, hexamethylene diamine, isomers of hexamethylene diamine, diethylene triamine, triethylene tetramine, tetraethylene pentamine, bishexamethylene triamine, N,N'-Bis(3-aminopropyl)- 1 ,2-ethane diamine, N-(3-Aminopropyl)-1 ,3-propane diamine, N-(2-aminoethyl)- 1 ,3 propane diamine, cyclohexane diamine, isomers of cyclohexane diamine, 4,4'-methylene biscyclohexane amine, 4'4'-methy!ene bis(2- methylcyclohexanamine), isophorone diamine, and phenalkylene polyamines.
• Aromatic amines may also be used as the amine cross linker. Suitable aromatic amines include, for example, di-(4-aminophenyl)suifone, di-(4- aminophenyl)ether, 2,2-bis(4-aminophenyl)propane, 4,4'-diamino
• diphenylmethane S.S'-dimethyM ⁇ '-diaminodiphenyl methane
• m-phenylene diamine p-phenylene diamine
• m-xylylene diamine toluene diamine
• 4,4'- methylene dianiline benzidine
• 4,4'-thiodianiline 4-methoxy-1 ,3-phenyldiamine, 2,6-diaminopyridine, and dianisidine.
• Polyether diamines may also be utilized as the amine cross linker.
• Suitable polyether diamines include, but are not limited to, 4,9-dioxadodecane- 1 ,12-diamine, 4,7,10-trioxatridecane-1 ,12-diarnine, bis(3-amino
• propyl)polytetrahydrofurans of varying molecular weights, and commercially available polyoxyalkylene amines from Texaco Chemical Co. under the
• the amine cross linker can be an amino functional polymer such as those sold under the JEFFAMINE ® brand, a poly(aHyl amine), poly(L-lysine) or other amino functional polymers such as a polyalkylene oxide, including PEG, PEO and PPO having two or more amine functional groups.
• the first component i.e., the functionalized triol
• the second component i.e., the functionalized diol component
• the third component i.e., the multifunctional polyol
• the at least one amine cross linker may be applied in an amount sufficient to enhance the polymerization of the components of the sealant composition which, in some embodiments, can be in an amount from about 1 to about 50 percent by weight of the sealant composition, typically from about 10 to about 25 percent by weight; of the sealant composition.
• the multifunctional polyol may be combined with the functionalized triol, optionally in combination with the second diol component, and at least one amine cross linker by any means known to those skilled in the art to form a sealant composition of the present disclosure.
• the multifunctional polyol and functionalized triol, optionally in combination with the second diol may be combined with the functionalized triol, optionally in combination with the second diol component, and at least one amine cross linker by any means known to those skilled in the art to form a sealant composition of the present disclosure.
• Suitable solvents include those that are water miscible and biologically
• the solvents can include DIGLYME (diethylene glycol dimethyl ether), N.N-dimethylformamide (“DMF”), dimethyl sulfoxide, and the like.
• DIGLYME diethylene glycol dimethyl ether
• DMF N.N-dimethylformamide
• dimethyl sulfoxide and the like.
• the at least one amine cross linker can be dissolved in an aqueous media which contains at least one biodegradable thickener to form a second component solution.
• Suitable biologically acceptable thickeners include disaccharides, polysaccharides, alginates, hyaluronic acid, pectins, dextrans, cellulosics such as carboxymethyl cellulose, methyl cellulose, and the like.
• the first component solution and the second component solution may then be combined upon application to form a sealant composition of the present disclosure.
• the final sealant composition of the present disclosure has several advantageous properties.
• the final sealant composition has a rapid curing time. Application of the sealant composition, with or without other additives, can be done by any conventional means.
• sealant composition may be utilized to avoid stress to the tissue and insure a uniform coating over the area.
• a dual-compartment applicator may be utilized and mixing of the first component solution and second component solution occurs to form a sealant upon dispensing by an aerosol or by means of a mixing head attached to the applicator or syringe.
• Other additives can be introduced into the first component solution, the second component solution, or both.
• the sealant, composition may be sprayed onto mammalian tissue, which lowers the risk of ⁇ idditional mechanical stress on the tissue.
• the spray application can be done by any means known to those skilled in the art such that the sealant composition can be applied as a fine mist or aerosol.
• the composition can be placed in a spray bottle and delivered with a hand pump.
• the composition can be placed in a container with a non- chlorofluorohydrocarbon propellant (e.g., air, nitrogen, carbon dioxide, and/or hydrocarbons) and delivered using a pressurized spray can. In either case, the composition is passed through a fine orifice to form a mist and delivered to the surgical location.
• a non- chlorofluorohydrocarbon propellant e.g., air, nitrogen, carbon dioxide, and/or hydrocarbons
• the sealant composition can be used in place of, or in combination with, sutures, staples, clamps and the like.
• Applications for the sealant compositions of the present disclosure include sealing tissues to prevent or control blood or other fluid leaks at suture or staple lines.
• the sealant composition can be used to seal or adhere delicate tissue together in place of conventional tools that may cause mechanical stress.
• the sealant composition can also be used to seal air and/or fluid leaks in tissue. Additionally, the sealant composition can be applied to tissue as a barrier to prevent adhesions, provide a protective layer for delicate damaged tissue and/or provide a drug delivery layer to a surgical site.
• the composition of the present disclosure can be used in surgery to prevent or inhibit bleeding or fluid leakage both during and after a surgical procedure. It can also be applied to prevent air leaks associated with pulmonary surgery.
• the sealant may be applied directly to the desired area in at least an amount necessary to seal off any defect in the tissue and seal off any fluid or air movement.
• the adhesive compositions of the present disclosure have been described as including a functionalized triol and a functionalized diol, and whereas the sealant compositions of the present disclosure have been described as including a functionalized triol, a functionalized diol, a multifunctional polyol and at least one amine cross linker, it is also contemplated that the adhesive compositions of the present disclosure could be used as sealants and the sealant compositions of the present disclosure could be used as adhesives.
• the desired properties of the biocompatible compositions of the present disclosure can be adjusted by the selection of the specific components utilized to prepare the resulting adhesive or sealant compositions.
• a variety of optional ingredients including medicinal agents may also be added to the biocompatible compositions of the present disclosure. These agents may be added to adhesive compositions of the present disclosure, sealant compositions of the present disclosure, or both.
• a phospholipid may also be added to the biocompatible compositions of the present disclosure. These agents may be added to adhesive compositions of the present disclosure, sealant compositions of the present disclosure, or both.
• surfactant that provides antibacterial stabilizing properties and helps disperse other materials in the biocompatible compositions may be added to the
• Additional medicinal agents include antimicrobial agents, colorants, preservatives, or medicinal agents such as, for example, protein and peptide preparations, antipyretic, antiphlogistic and analgesic agents;, anti-inflammatory agents, vasodilators, antihypertensive and antiarrhythmic agents, hypotensive agents, antitussive agents, antineoplastics, local anesthetics, hormone preparations, antiasthmatic and antiallergic agents, antihistaminics, anticoagulants, antispasmodics, cerebral circulation and metabolism improvers, antidepressant and antianxiety agents, vitamin D preparations, hypoglycemic agents, antiulcer agents, hypnotics, antibiotics, antifungal agents, sedative agents, bronchodilator agents, antiviral agents and dysuric agents.
• medicinal agents such as, for example, protein and peptide preparations, antipyretic, antiphlogistic and analgesic agents;, anti-inflammatory agents, vasodilators,
• Imaging agents such as iodine or barium sulfate, or fluorine, can also be combined with the compositions of the present disclosure to allow visualization of the surgical area through the use of imaging equipment, including X-ray, MRI, and CAT scan.
• an enzyme may be added to the compositions of the present disclosure to increase their rate of degradation.
• Suitable enzymes include, for example, peptide hydrolases such as elastase, cathepsin G, cathepsin E, cathepsin B, cathepsin H, cathepsin L, trypsin, pepsin, chymotrypsin, ⁇ glutamyltransferase ( ⁇ -GTP) and the like; sugar chain hydrolases such as phosphorylase, neuraminidase, dextranase, amylase, lysozyme, oligosaccharase and the like; oligonucleotide hydrolases such as alkaline phosphatase,
• the enzyme may be included in a liposome or microsphere to control the rate of its release, thereby controlling the rate of degradation of the composition of the present disclosure.
• compositions have a number of advantageous properties.
• the resulting compositions of the present disclosure are safe and biocompatible, possess enhanced adherence to tissue, are biodegradable, have hemostatic potential, have low cost, and are easy to prepare and use.
• the strength and elasticity of the adhesive and/or sealant composition can be controlled, as can the gelation time.
• the compositions rapidly form a compliant gel matrix, which insures stationary positioning of tissue edges or implanted medical devices in the desired location where the composition is utilized as an adhesive, and a tightly adherent yet flexible seal where the composition is used as a sealant. In either case, the rapidity of gelation lowers the overall required surgical/application time.
• compositions exhibit little or no swelling upon gel matrix formation, and therefore retain the positional integrity of the tissue to which the composition is applied and/or location of a medical device.
• the compositions form strong cohesive bonds, based in part on a low percent of water content as compared to other adhesive and sealant compositions. They exhibit excellent mechanical performance and strength, while retaining the necessary pliability to adhere living tissue. This strength and pliability allows a degree of movement of tissue without shifting the surgical tissue edge. Additionally, the compositions are
• compositions in accordance with this disclosure can be blended with other biocompatible, bioabsorbable or non-bioabsorbable materials.
• optional ingredients such as dyes, fillers, medicaments or antimicrobial compounds can be added to the composition. Therefore, the above description should not be construed as limiting, but merely as exemplifications of typical embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Materials Engineering (AREA)
• Surgery (AREA)
• Hematology (AREA)
• Materials For Medical Uses (AREA)
• Adhesives Or Adhesive Processes (AREA)
• Surgical Instruments (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=38123457

Family Applications (1)

Country Status (6)

Cited By (10)

Families Citing this family (21)

Family Cites Families (126)

• 2006
  • 2006-12-06 WO PCT/US2006/046554 patent/WO2007067623A2/en not_active Ceased
  • 2006-12-06 AU AU2006321913A patent/AU2006321913B2/en not_active Ceased
  • 2006-12-06 CA CA 2628582 patent/CA2628582C/en not_active Expired - Fee Related
  • 2006-12-06 EP EP06844892A patent/EP1968617A4/en not_active Withdrawn
  • 2006-12-06 US US11/635,294 patent/US7998466B2/en not_active Expired - Fee Related
  • 2006-12-06 JP JP2008544473A patent/JP5088894B2/ja not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events